



Addressing Challenges in Diagnosis and Treatment of Low-Grade Upper Tract Urothelial Carcinoma

REFERENCES

1. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.05.042
2. Monteiro LL, Witjes JA, Agarwal PK, et al. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. *World J Urol*. 2019;37(1):51-60. doi:10.1007/s00345-018-2438-9
3. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology*. 1999;116(6):1453-1456. doi:10.1016/s0016-5085(99)70510-x
4. Brown GA, Matin SF, Busby JE, et al. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. *Urology*. 2007;70(2):252-256. doi:10.1016/j.urology.2007.03.051
5. Thompson RH, Krambeck AE, Lohse CM, Elliott DS, Patterson DE, Blute ML. Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. *Urology*. 2008;71(4):713-717. doi:10.1016/j.urology.2007.11.018
6. Petros FG, Li R, Matin SF. Endoscopic approaches to upper tract urothelial carcinoma. *Urol Clin North Am*. 2018;45(2):267-286. doi:10.1016/j.ucl.2017.12.009
7. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. *Cancer*. 2009;115(6):1224-1233. doi:10.1002/cncr.24135
8. Petros FG, Qiao W, Singla N, et al. Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma. *Urol Oncol*. 2019;37(4):292.e291-292.e299. doi:10.1016/j.urolonc.2018.12.002
9. Freifeld Y, Ghandour R, Singla N, et al. Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. *Urol Oncol*. 2019;37(10):758-764. doi:10.1016/j.urolonc.2019.06.009
10. Xylinas E, Rink M, Margulis V, et al. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. *BJU Int*. 2013;112(4):453-461. doi:10.1111/j.1464-410X.2012.11649.x
11. Yakoubi R, Colin P, Seisen T, et al. Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: a meta-analysis and a systematic review of current evidence from comparative studies. *Eur J Surg Oncol*. 2014;40(12):1629-1634. doi:10.1016/j.ejso.2014.06.007
12. O'Brien T, Ray E, Singh R, Coker B, Beard R. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). *Eur Urol*. 2011;60(4):703-710. doi:10.1016/j.eururo.2011.05.064
13. Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. *J Clin Oncol*. 2013;31(11):1422-1427. doi:10.1200/jco.2012.45.2128
14. Messing EM, Tangen CM, Lerner SP, et al. Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on



Addressing Challenges in Diagnosis and Treatment of Low-Grade Upper Tract Urothelial Carcinoma

tumor recurrence: SWOG S0337 randomized clinical trial. *JAMA*. 2018;319(18):1880-1888. doi:10.1001/jama.2018.4657

15. Huffman JL, Bagley DH, Lyon ES, Morse MJ, Herr HW, Whitmore WF, Jr. Endoscopic diagnosis and treatment of upper-tract urothelial tumors. A preliminary report. *Cancer*. 1985;55(6):1422-1428. doi:10.1002/1097-0142(19850315)55:6<1422::aid-cnrcr2820550642>3.0.co;2-f
16. Audenet F, Traxer O, Bensalah K, Rouprêt M. Upper urinary tract instillations in the treatment of urothelial carcinomas: a review of technical constraints and outcomes. *World J Urol*. 2013;31(1):45-52. doi:10.1007/s00345-012-0949-3
17. Giannarini G, Kessler TM, Birkhäuser FD, Thalmann GN, Studer UE. Antegrade perfusion with bacillus Calmette-Guérin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? *Eur Urol*. 2011;60(5):955-960. doi:10.1016/j.eururo.2011.07.051
18. Foerster B, D'Andrea D, Abufaraj M, et al. Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. *Urol Oncol*. 2019;37(7):430-436. doi:10.1016/j.urolonc.2019.02.004
19. Kleinmann N, Matin SF, Pierorazio PM, et al. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. *Lancet Oncol*. 2020;21(6):776-785. doi:10.1016/s1470-2045(20)30147-9